Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 15Gynecologic 6Sarcoma 3Breast 3Plasma cell 1Lymphoid 1Genitourinary 1

Conditions

Sarcoma 9Osteosarcoma 4Sarcoma, Ewing 3Rhabdomyosarcoma 3Neuroblastoma 3Neoplasms 3Medulloblastoma 3Glioma 3Central Nervous System Neoplasms 3Carcinosarcoma 3Wilms Tumor 2Rhabdoid Tumor 2Recurrence 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Endometrial Neoplasms 2Carcinoma, Endometrioid 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Prostatic Neoplasms 1Pheochromocytoma 1Pathologic Complete Response 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × olaparib × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn
Sarcoma

Liposarcoma, Neoplasms, Sarcoma

NCT03570437 2022-03-02

COPELIA

University of Manchester

Phase 2 Unknown
124 enrolled
GynecologicSarcoma

Carcinosarcoma, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡